BMO Capital Downgrades Globus Medical to Market Perform, Lowers Price Target to $78
Benzinga Newsdesk 15 hours ago
Analyst RatingsNewsDowngradesPrice Target
BMO Capital analyst Vik Chopra downgrades Globus Medical (NYSE:GMED) from Outperform to Market Perform and lowers the price target from $94 to $78.
BMO Capital analyst Vik Chopra downgrades Globus Medical (NYSE:GMED) from Outperform to Market Perform and lowers the price target from $94 to $78.